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Anticancer Activity Driven by Drug Linker Modification in  
a Polyglutamic Acid-Based Combination-Drug Conjugate
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Esther Masiá, Alison Paul, Craig James, Ana Armiñán,* and María J. Vicent*
Combination nanotherapies for the treatment of breast cancer permits 
synergistic drug targeting of multiple pathways. However, poor carrier 
degradability, poor synergism of the combined drugs, low drug release 
regulation, and a lack of control on final macromolecule solution conforma-
tion (which drives the biological fate) limit the application of this strategy.  
The present study describes the development of a family of drug delivery 
systems composed of chemotherapeutic (doxorubicin) and endocrine therapy 
(aromatase inhibitor aminoglutethimide) agents conjugated to a biodegrad-
able poly-l-glutamic acid backbone via various linking moieties. Data from 
in vitro cytotoxicity and drug release assessments and animal model valida-
tion select a conjugate family member with optimal biological performance. 
Exhaustive physicochemical characterization in relevant media (including the 
study of secondary structure, size measurements, and detailed small-angle 
neutron scattering analysis) correlates biological data with the intrinsic supra-
molecular characteristics of the conjugate. Overall, this study demonstrates 
how a small flexible Gly linker can modify the spatial conformation of the 
entire polymer–drug conjugate, promote the synergistic release of both drugs, 
and significantly improve biological activity. These findings highlight the need 
for a deeper understanding of polymer–drug conjugates at supramolecular 
level to allow the design of more effective polymer–drug conjugates.
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complex and heterogeneous disease that 
often metastasizes and/or becomes drug 
resistant.[3] There currently exist a wide 
range of strategies under investigation, 
including the liposomal entrapment of 
Cytarabine and Daunorubicin (US Food 
and Drug Administration (FDA) approved 
Vyxeos, formerly CPX-351), which has 
improved all efficacy parameters, including 
overall survival, in a Phase 3 clinical trial of 
high-risk acute myeloid leukemia patients.[4]
Polymeric therapeutics (PT) as single 
agent or as combination therapeutics 
offer numerous advantages over conven-
tional drugs, including the possibility of 
an enhanced passive accumulation via 
the enhanced permeability and retention 
(EPR) effect on those tumors adequately 
vascularized,[5] or the ability to cross 
specific biological barriers.[6] Moreover, 
drug(s) conjugation to a polymeric carrier 
benefits from several additional advan-
tages[7,8] as an optimized drug pharma-
cokinetics, multivalence that allows the 
conjugation of multi ple active/imaging 
agents and targeting moieties,[2,9] and 
the ability to target drug activity to tumors via bioresponsive 
poly mer–drug linkers.[10] One issue limiting the widespread use 
of polymer conjugates is the current lack of understanding of 
the complex interplay of dynamic physicochemical factors, such 
as size, shape, surface chemistry, roughness, rigidity, and the 
influence of linkers and active agents, which characterize the 
interaction of nanosized PTs with the biological interface.[11]
We developed the first polymer–drug combination conjugate, 
an N-(2-hydroxypropyl) methacrylamide copolymer carrying 
both aminogluthetimide and doxorubicin (HPMA-AGM-Dox), 
with the aim of combining an aromatase inhibitor with a chem-
otherapeutic agent for the treatment of chemotherapy-resistant 
breast cancer.[12–14] HPMA-AGM-Dox displayed enhanced in 
vitro breast cancer cell toxicity compared to a combination of the 
unconjugated drugs or individual polymer–drug conjugates.[12,13] 
Recently, in vivo proof of concept for antitumor drug synergism 
with the combination conjugate has been also achieved in an 
aggressive metastatic 4T1 murine breast cancer model.[14] The 
mechanism of the enhanced activity appeared primarily due to 
the kinetics of drug release and the fact that both drugs were 
made “bioavailable” in the same cell at the same time. Impor-
tantly, when protein expression of tumor tissue samples were 
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1. Introduction
Combination anticancer strategies within nanomedicine may rep-
resent an efficient means to treat breast cancer,[1,2] a molecularly 
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analyzed, strong differences were observed in tumor-associated 
angiogenesis pathways, which could only be explained by the 
simultaneous estrogen inhibition induced by AGM, only made 
available at the appropriate cell and time with the combination 
conjugate. This effect was enhanced by an autophagic cell death 
mechanism only associated with the combination conjugate.[14] 
These results demonstrated for the first time that the rational 
design of a combination PT could significantly enhance drug 
therapeutic output while also significantly reducing the side 
effects and tissue damage observed when applying the uncon-
jugated forms of these active agents. This concept has been fur-
ther explored and reinforced both in vitro and in vivo through 
studies in our laboratory and other research groups.[2]
However, despite these promising findings, preclinical evi-
dence of detrimental side effects derived from the chronic use 
of biopersistent polymer carriers (i.e., HPMA or polyethylene 
glycol, PEG)[15] have led to an exponentially growing research 
interest on biodegradable polymers, in particular, polypeptides 
such as poly-l-glutamic acid (PGA)[10,16] as clinical benefits have 
been achieved with polypeptide based polymeric drugs, such as 
Copaxone[17] (one of the top ten selling drugs)[8,18] and the les-
sons learnt with PGA-based anticancer PTs such as Opaxio.[19]
Encouraged by the successful application of PGA to conjugate 
chemotherapy as single agents[19] and in combination,[20,21] as well 
as our prior data combining endocrine and chemotherapy,[12–14] 
we now describe the first PGA-based combination conjugates 
bearing chemotherapy and estrogen modulator agents for the 
treatment of breast cancer. Furthermore, we took this opportu-
nity to explore how the incorporation of different polymer–drug 
linkers influences conjugate characteristics and biological fate. 
Implementing a rational experimental design, we systemati-
cally prescreened a family of single and combination conjugates, 
provided with different drug loadings and linkers, in vitro in a 
breast cancer cell line, and then selected successfully screened 
conjugates for further assessments in an aggressive orthotopic 
4T1 breast cancer murine model. We also studied the spatial 
conformation and physical structure of our conjugate family 
in biological milieu to predict and better understand intrinsic 
interactions with the nanobiointerface and therefore, therapeutic 
effect and mechanisms of action. Parameters assessed included 
drug release kinetics in the presence of lysosomal enzymes as 
well as 3D conformation including secondary structure, size, and 
shape by dynamic light scattering (DLS), small angle neutron 
scattering (SANS), and circular dichroism (CD). We present the 
selected PGA-based drug-combination conjugate as an exciting 
therapeutic candidate, underlining that the choice and/or design 
of drug–polymer linkers may allow tight spatiotemporal con-
trol of drug release and the enhanced personalized treatment of 
aggressive breast cancer.
2. Results and Discussion
2.1. Synthesis and Characterization of Polymer–Drug Conjugates
We employed optimized and scalable synthetic method-
ologies to develop a rationally designed family of polymer-
based combination anticancer conjugates using n-butyl PGA 
(100 units, Mw ≈ 13 kDa) as a biodegradable carrier, with the 
aim of achieving drug synergism. Aromatase inhibitors, such 
as aminoglutethimide (AGM), induce apoptosis[22] and can act 
synergistically when combined with chemotherapeutics,[23] as 
previously shown in our studies with HPMA-based combina-
tion conjugates.[12–14] Although HPMA has demonstrated its 
suitability as carrier for anticancer treatments, we expected that 
replacing HPMA with PGA would improve safety issues spe-
cially in chronic administrations given its enhanced biodegra-
dability. This improved characteristic would reduce unwanted 
side effects related to polymer accumulation as seen with other 
nonbiodegradable carrier such as PEG.[15,24]
Therefore, we developed a library of well-defined PGA-
conjugates via carbodiimide coupling (Figure 1).[12,25] We also 
synthesized and fully characterized single-agent PGA conjugates 
bearing Dox or AGM for comparative purposes (Table 1 summa-
rizes data on all conjugates assessed). We introduced Dox directly 
and AGM via direct amide conjugation, a Gly linker (G),[26] a 
Gly–Gly linker (GG),[27] or the well-known tetrapeptidic Gly-Phe-
Leu-Gly linker (GFLG), which is cleaved by the lysosomal thiol-
dependent protease Cathepsin B.[28] To explore the effect of two 
different therapeutic scenarios, we fixed Dox content within the 
polymer conjugate at 5% mol, but varied AGM from 5% mol 
(low loading [LL]) to 10% mol (high loading [HL]) (Figure 1A). 
Additionally, we also incorporated both drugs within the same 
PGA chain to create a family of combination conjugates. Impor-
tantly, the robust methodology employed and tight controls on 
drug loading permitted the scale-up of this process to gram-scale 
batches without losses in either conjugation efficiency or yield. 
Prior to characterization, we isolated and purified all conjugates 
by size exclusion chromatography (SEC) to remove any excess 
of salts, activating agents or traces of unreacted drugs (see 1C, 
Supporting Information, for a detailed synthetic methodology).
1H NMR characterization of the synthesized products was 
used to determine their identity and purity. As demonstrated in 
Figure 1B, which displays spectra of representative conjugates, 
the covalent incorporation of a single drug (PGA-(G-AGM)LL, 
PGA-Dox), or the drug combination (PGA-(G-AGM)LL-Dox) 
into the polymer backbone resulted in the expected widening 
of characteristic drug signals (see Figures S11 and S12, Sup-
porting Information, for details on family characterization). The 
signal of the Dox methylene group at 1.2 ppm and the signals 
corresponding to the aromatic ring (0.75 ppm) and ethylene 
group (7.4 ppm) of AGM permitted identity verification for 
both the single and combination nanoconjugates. As shown in 
Figure 1C, representative conjugates displayed a homogeneous 
distribution of drug content along the polymer population (as 
derived from the SEC elution profiles in UV–vis at 260 nm). 
These profiles conformed to the expected behavior according to 
size, as different conjugates exhibited slightly shorter retention 
times and broader peaks when compared with parental uncon-
jugated/unmodified PGA (Figure 1C), in accordance with the 
enhanced Mw due to the incorporation of drugs.
2.2. Quantitative Characterization of Total Drug Loading 
and Free Drug Content in PGA–Drug Conjugates
Despite the lower reactivity of the aromatic amine present in AGM, 
we found the synthetic carbodiimide-activation methodology 
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to be a good and reproducible approach (Table 1) for both the 
single and combination conjugates. We noted that conjugation 
yield improved significantly when we first incorporated AGM 
with different peptidic linkers, and so we performed amide cou-
pling through a primary peptidic amine rather than through the 
primary aromatic amine of the drug. We also noted efficient con-
jugation of Dox, except for combination conjugates bearing the 
GFLG-AGM moiety. Lower Dox loading in the presence of the 
bulky GFLG-AGM moiety may be due to steric hindrance, which 
can limit high levels of Dox incorporation. We also found that an 
SEC-based purification procedure ensured low levels of free-drug 
in the final conjugates ranging from 0.1% to 0.7% w/w for Dox and 
0.2–1.1% w/w for AGM (Table 1). Absolute Mw analysis by ana-
lytical tandem SEC-multi angle light scattering (MALS)-refractive 
index (RI) proved difficult due to heterogeneity in drug loadings 
and the inherent nature of the conjugates, so we calculated the 
theoretical molecular weight of PGA conjugates according to the 
percentage of modification (range: 12.7–18.6 kDa).
2.3. Preliminary In Vitro Evaluation and Drug Release Kinetics 
of PGA Conjugates
To assess the biological implications of different drug linkers 
and drug ratios in the synthesized conjugates, we undertook a 
wide-ranging preliminary in vitro screening of the PGA-AGM-
Dox family of conjugates. This analysis also compared treat-
ment with the various PGA-AGM conjugates and PGA-Dox as 
Adv. Funct. Mater. 2018, 1800931
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Figure 1. A) Synthetic route for the preparation of single and combination PGA-drug conjugates: 1) Carbodiimide-based carboxylic group activation. 
2) Attachment of Dox or AGM (or derivatives) for single conjugates, and Dox coupling as the second drug in the combination conjugates. 3) Conversion 
into polycarboxilate form. B) Representative 1H-NMR spectra (D2O, 500 MHz) and C) representative SEC chromatograms for parental PGA (RI detection, 
peak at 17.1 corresponds to the counter-cation Na+) and PGA-Dox, PGA-(G-AGM)LL, and PGA-(G-AGM)LL-Dox conjugates (UV at 260 nm).
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two separate species added simultaneously (i.e., drugs were not 
present in the same polymeric chain).
Cell viability assays in the MCF-7ca breast cancer cell line 
demonstrated higher cytotoxicity for the combination conju-
gates PGA-(GG-AGM)LL-Dox (Figure 2B), PGA-(G-AGM)LL-Dox 
(Figure 2C), and PGA-(G-AGM)HL-Dox (Figure 2D) when com-
pared with the single PGA-Dox and PGA-AGM parent conju-
gates alone or in a physical combination (Table 2). The PGA-
(AGM)LL-Dox (Figure 2A), PGA-(GFLG-AGM)LL-Dox (Figure 2E), 
and PGA-(GFLG-AGM)HL-Dox (Figure 2F) did not display 
high toxicity compared to PGA-Dox at tested concentrations. 
We found evidence of poor Dox release in the combination 
conjugates bearing GFLG-AGM (see Figure S13, Supporting 
Information), which is a requisite for cell toxicity. This fact 
may be due to intramolecular hydrophobic interactions that 
could trigger steric hindrance and, therefore, restricted access 
of proteases to the Dox linker. Of note, the physical combina-
tion of single drug conjugates administered at the same time 
(Figure 2A,E,F) did mediate an enhanced cytotoxic effect when 
compared to the combination conjugates. However, whole body 
pharmacokinetics and conjugate interaction with biological bar-
riers in vivo play a determinant role and, therefore, the admin-
istration of two single conjugates to a patient will not ensure 
that both drugs will arrive at the same target cell at the desired 
ratio and within the required period, making this treatment 
strategy ultimately inefficient for our selected molecular targets.
As previous studies demonstrated significant synergism 
between AGM and Dox in the different breast cancer cells 
when incorporated within the same nonbiodegradable poly-
meric carrier,[12–14] we computed the combination index (CI) 
for our new biodegradable systems against MCF-7-ca.[29] 
These calculations discovered no synergistic effects when we 
treated cells with both drugs as separate single conjugates 
(Figure S1, Supporting Information—
PGA-(AGM)LL + PGA-Dox, PGA-(GG-
AGM)LL + PGA-Dox, PGA-(G-AGM)LL + PGA-
Dox, and PGA-(G-AGM)HL + PGA-Dox), 
except for the PGA-(GFLG-AGM)LL and 
PGA-Dox treatment, which provided the 
lowest CI value of 0.3. However, we did 
observe high levels of synergism (CI < 1) 
for the PGA-(G-AGM)LL-Dox (0.32), PGA-(G-
AGM)HL-Dox (0.32), and PGA-(GG-AGM)LL-
Dox (0.33) combination conjugates (Figure 
S1, Supporting Information), with a weaker 
synergistic effect observed for PGA-(GFLG-
AGM)LL-Dox (0.56).
We noted that the presence of the linker 
drastically modified the in vitro cytotoxic 
effects; the addition of small, short, and flex-
ible Gly or Gly–Gly linkers led to enhanced 
results when compared to direct linkage 
of AGM or through the more bulky GFLG 
linker. Additionally, we assessed cell toxicity 
of two highly synergistic conjugates found 
in the previous study in murine 4T1 breast 
cancer cells as a first step toward studying 
conjugate antitumor activity in an orthotopic 
immunocompetent mammary tumor mouse 
model. The PGA-(G-AGM)LL-Dox (IC50 = 0.0034 mg mL−1 Dox 
equiv.) and PGA-(G-AGM)HL-Dox (IC50 = 0.0033 mg mL−1 Dox 
equiv.) conjugates presented higher cytotoxicity compared to 
the single conjugate PGA-Dox (IC50 = 0.0084 mg mL−1 Dox 
equiv.) (Figure 3A,B, respectively, and Figure S2, Supporting 
Information). We also assessed cell toxicity of PGA-(AGM)LL-
Dox as a control for nonsynergistic effect (Figure 3C) and, as 
expected, this combination conjugate displayed a higher IC50 
value (0.012 mg mL−1 Dox equiv.) than the combination con-
jugates bearing the Gly spacer. In general, we observed a more 
pronounced cytotoxic activity in 4T1 cells than in MCF-7-ca, 
probably due to the higher level of Cathepsin B activity in 4T1 
cells,[14] which degrades the peptidic polymer–drug linkers and 
the poly-l-glutamic acid carrier. Subsequent CI value calcula-
tions found strong synergism for the PGA-(G-AGM)HL-Dox 
conjugate (CI = 0.176) (Figure S2, Supporting Information).
We also evaluated drug release kinetics in presence of 
Cathepsin B for the PGA-(G-AGM)LL-Dox, PGA-(G-AGM)HL-
Dox, and PGA-(AGM)LL-Dox conjugates (Figure 3D–F), 
finding three different release profile scenarios as a con-
sequence of drug loadings and linker type. The PGA-(G-
AGM)LL-Dox conjugate displayed a significantly faster and 
higher release of AGM (13% after 72 h) in contrast to Dox 
(7%) during the same time period. However, the PGA- 
(G-AGM)HL-Dox conjugate released higher amount of Dox 
(12% at 72 h) as compared to lower levels of AGM (3%) 
over the same time. Meanwhile, the PGA-(AGM)LL-Dox 
conjugate displayed a simultaneous release profile for both 
drugs (≈10%) over 72 h. PGA-(G-AGM)HL-Dox and PGA-
(G-AGM)LL-Dox differ only in their level of AGM loading, 
with higher loading significantly diminishing drug release 
kinetics, perhaps due to structural modifications in the 
poly mer chain. However, we noted a similar cytotoxic effect 
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Table 1. Characteristics of PGA-AGM-Dox polymer–drug conjugates.
  Compound Total druga)  
[%w/w]
Free drugb)  
[%w/w to total drug]
Mwc)  
[Da]
Total drug  
[%mol]
AGM Dox AGM Dox – AGM Dox
PGA – – – – 12 700 – –
PGA-(AGM)LL 6.8 – 1.1 – 13 600 4.0 –
PGA-(G-AGM)LL 9.1 – 0.9 – 13 900 4.7 –
PGA-(G-AGM)HL 17.8 – 0.7 – 15 450 9.5 –
PGA-(GG-AGM)LL 10.8 – 0.9 – 14 200 4.4 –
PGA-(GFLG-AGM)LL 10.4 – 0.2 – 14 800 2.5 –
PGA-(GFLG-AGM)HL 18.8 – 0.4 – 15 650 4.8 –
PGA-(Dox) – 14.2 – 0.1 14 800 – 3.9
PGA-(AGM)LL-Dox 8.1 15.8 0.8 0.4 16 700 5.8 4.8
PGA-(G-AGM)LL-Dox 7.8 20.1 1.1 0.3 17 600 5.61 6.5
PGA-(G-AGM)HL-Dox 20.1 12.7 1.0 0.4 18 900 13.1 4.4
PGA-(GG-AGM)LL-Dox 7.6 18.9 0.9 0.2 17 300 3.8 6.0
PGA-(GFLG-AGM)LL-Dox 12.4 7.1 0.3 0.7 15 800 3.2 2.0
PGA-(GFLG-AGM)HL-Dox 24.2 7.6 0.4 0.7 18 600 7.4 2.6
a)Determined by UV–vis (AGM) and HPLC (Dox); b)Determined by HPLC; C)Determined by aqueous SEC 
MALS-RI for the sodium salt form of PGA. Mw of the polymer–drug conjugates were estimated from total 
drug loading.
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for both LL and HL conjugates, possibly mediated through 
different molecular mechanisms. While high Dox release 
from the PGA-(G-AGM)HL-Dox can enhance cytotoxicity, high 
AGM release from the PGA-(G-AGM)LL-Dox conjugate may 
enhance cell sensitivity to Dox[13,14] and provide a synergistic 
effect even given the lower levels of Dox release. Aromatase 
inhibitors such as AGM promote apoptosis[22] and this may 
also sensitize cancer cells to Dox treatment. In a direct com-
parison between PGA-(AGM)LL-Dox and PGA-(G-AGM)LL-Dox 
conjugates, which only differ in the addition of the small flex-
ible Gly linker, enhanced AGM release seems to be related 
with structural alteration promoted by Gly. In terms of drug 
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Figure 2. Cell toxicity study of polymer drug conjugates in MCF-7-ca cells. Cell viability measured by MTS assay after 72 h of treatment. A) PGA-
(AGM)LL-Dox, B) PGA-(GG-AGM)LL-Dox, C) PGA-(G-AGM)LL-Dox, D) PGA-(G-AGM)HL-Dox, E) PGA-(GFLG-AGM)LL-Dox, and F) PGA-(GFLG-AGM)HL-
Dox. Every assay is displayed with its corresponding single conjugates and Dox as free drug control. Data expressed as mean ± standard error of the 
mean (SEM), at least n = 3 experiments per treatment.
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synergism, we found that Gly presence induced synergism 
while the absence of Gly brings drug antagonism.
Drug release required the strategic design of the family of poly-
peptide–drug conjugates toward lysosomotropic delivery, where 
the enzymatic degradation of the polymeric chain will release the 
active agents at the desired site of action. This not only improves 
therapeutic efficiency but also reduces unwanted off-target side 
effects. The degradation process requires efficient cellular uptake 
and adequate access of the endopeptidase to the linker,[30] with 
accessibility directly related with the 3D spatial disposition of 
the polypeptide. This in turn is influenced by structural factors 
such as conjugated moieties,[31] drug loadings,[32] drug ratios,[33] 
linking chemistry, and physicochemical descriptors mediating 
the nanobiointerface.[10,34] At this point, in vitro behavior of the 
conjugates cannot be explained by taking into account drug load-
ings and linking chemistry solely, although it seems clear that 
under the same PGA-Dox linking chemistry and drug loading, 
incorporation of AGM at different ratios or through different 
linkers could explain the observed results.
2.4. Antitumor Evaluation and Biodistribution of Selected 
Conjugates in a 4T1 Orthotopic Breast Cancer Murine Model
The conjugation of active agents to a biodegradable polymer 
provides distinct advantages over conventional monotherapy 
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Figure 3. Cell toxicity analysis of the polymer drug conjugates A) PGA-(G-AGM)LL-Dox and B) PGA-(G-AGM)HL-Dox in 4T1 cells. C) Comparative study 
of cell toxicity of PGA-(G-AGM)LL-Dox, PGA-(G-AGM)HL-Dox, and PGA-(AGM)LL-Dox. Cell viability measured by MTS assay after 72 h of the treatment. 
Drug release kinetics in presence of Cathepsin B of D) PGA-(G-AGM)LL-Dox, E) PGA-(G-AGM)HL-Dox, and F) PGA-(AGM)LL-Dox. Data expressed as 
mean ± SEM, at least n = 3 experiments per treatment.
Table 2. Summary of main physicochemical and biological descriptors of the selected polymer–drug conjugates.
Polymer–drug 
conjugate
Cytotoxicity human 
MCF-7-ca
Cytotoxicity murine  
4T1
Size (RH)  
(By number)
Cellular  
uptake
Secondary 
structure trend
Antitumor 
activity
Drug release SANS
PGA-(AGM)LL- 
Dox
Low 
(IC50 = 0.53 mg mL−1)
Sparingly 
(IC50 = 0.012 mg mL−1)
≈100 nm High Alpha-helix Noneffective Simultaneous Larger, noncompact aggregates.  
No evidence of internal ordering
PGA-(G-AGM)
LL-Dox
High 
(IC50 = 0.003 mg mL−1)
High 
(IC50 = 0.0034 mg mL−1)
≈20 nm Low Random coil Effective AGM first  
and faster
Larger compact aggregates.  
Some internal ordering
PGA-(G-AGM)
HL-Dox
High 
(IC50 = 0.0017 mg mL−1)
High 
(IC50 = 0.0033 mg mL−1)
≈4 nm Low Alpha-helix Highly 
effective
Dox first  
and faster
Smaller, more compact aggregates. 
No evidence of internal ordering
PGA-(GG-AGM)
HL-Dox
High 
(IC50 = 0.0011 mg mL−1)
N/A ≈7 nm Low Random coil N/A N/A Large compact aggregates. 
Internally ordered
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strategies. These include passive accumulation of the combi-
nation conjugate in solid tumors thanks to the EPR effect[5] as 
well as the simultaneous delivery of both drugs at the tumor 
site of action.[9] Given tumor complexity, modulating the activity 
of two pathways will often provide greater therapeutic effects 
than monotherapies. In addition, polymer conjugation permits 
enhanced blood circulation times that allows sustained bio-
availability and conjugate accumulation in tumor vessels, so 
leading to enhanced therapeutic output. The orthotopic mouse 
4T1 breast tumor model has several characteristics that make 
an attractive experimental model to mimic breast cancer[35] 
including the well vascularized nature of the tumor,[36] which is 
a prerequisite for the EPR effect.
In order to explore the antitumor effect of the nanosystems 
under study, we randomly split mice inoculated with 4T1 cells 
into representative groups and scheduled three treatments 
every three days with selected combination conjugates and their 
corresponding single conjugates at 10 mg kg−1 Dox equiv. We 
administered Dox as a free agent in a control group at the max-
imum nonlethal dose (3 mg kg−1).[14] Analysis of tumor growth 
along time (Figure 4A) demonstrated high intragroup uni-
formity allowing us to effectively evaluate the antitumor effect 
of different treatments. Treatment with the single conjugates 
bearing AGM, Dox, the addition of either single conjugate, or 
free Dox did not significantly affect tumor growth. However, we 
observed a synergistic antitumor effect in animals treated with 
the PGA-(G-AGM)LL-Dox and PGA-(G-AGM)HL-Dox combina-
tion conjugates, as compared with the single conjugates (alone 
or added simultaneously) and controls (unconjugated PGA or 
phosphate buffered saline (PBS)) (Figure 4A).
We assessed safety profiles for all tested polymer–drug 
conjugates via the study of body weight, general wellbeing, 
behavior, and histopathology of specific organs. We did not 
observe significant alterations in body weight of treated ani-
mals (Figure 4C) and histological study of the kidney and liver 
displayed no pathological tissue alterations related with any 
conjugate-based treatment, confirming the in vivo safety of this 
family of polymer–drug conjugates (see Figure S14, Supporting 
Information, for details). Subsequent analysis of survival rates 
(Figure 4B) demonstrated that PGA-(G-AGM)LL-Dox and PGA-
(G-AGM)HL-Dox treated mice survived longer than other treated 
mice (controls or single treatments).
We next studied biodistribution and pharmacokinetics for 
a representative conjugate with high antitumor activity (PGA-
(G-AGM)HL-Dox) and compared the treatment with conven-
tional Dox intravenous (i.v.) administration as a monotherapy 
in the 4T1 tumor model. Passive tumor accumulation reached 
a maximum accumulation time at 4 h after i.v. administration 
(59-fold in comparison with free Dox, Figure 4D). We also 
detected conjugate accumulation in the heart and spleen, 
although at a significantly lower level (Figure 4E). Given the 
small size of the conjugate tested, we also expected kidney 
and liver accumulation due to renal excretion as well as clear-
ance by the reticuloendothelial system (Figure 4E), which 
may be promoted by the altered conformation of the combi-
nation conjugate.[37] To perform the pharmacokinetics study, 
we analyzed plasma samples of treated animals at different 
times (basal, 0.5, 1, 4, and 24 h) and quantified Dox accumu-
lation by high performance liquid chromatography (HPLC) 
(Figure 4F). We observed a similar blood circulation time 
profile for the combination polymer conjugate in compar-
ison with free Dox. However, while we did not detect Dox at 
30 min postadministration of the free Dox form, we did detect 
Dox following combination conjugate treatment, resulting in 
a nine-times higher PGA-(G-AGM)HL-Dox accumulation half-
life (t½α = 0.4 h) when compared to free Dox (t½α = 0.09 h) 
(Figure 4G). These data agree with previous studies.[14,37]
2.5. Physicochemical Evaluation of Selected Conjugates 
and Cellular Uptake
The conjugation of single drugs and combinations of drugs 
influences conjugate size and conformation, and these effects 
modify the biophysical properties and thus the pharmacoki-
netic and biodistribution profile of the resultant conjugate. 
Conjugated moieties introduce new spatial and charged ele-
ments that change the electrostatic equilibrium of the whole 
anionic polypeptide.[10] While the behavior of our conjugates in 
the animal model can be explained by the drug release kinetics, 
drug synergism profiles, and the in vitro analyses, any correla-
tion between drug loadings, linking chemistry, and in vivo fate 
remains unsolved. Such correlations are driven by an intricate 
and complex interplay of interconnected factors. The lack of 
descriptive elements to predict biological output within this 
family of polymer–drug conjugates motivated us to carry out 
a more detailed physicochemical characterization of the conju-
gates, looking at conformational and structural/morphological 
features that might allow us to rationalize the observed biolog-
ical performance.
At the molecular level, secondary structure analysis by CD 
(Figure 5A) demonstrated that PGA-(G-AGM)LL-Dox clearly 
deviated from the expected random coil conformation of the 
polyanionic PGA toward a partial alpha-helix conformation.[38] 
We performed measurements in 10 × 10−3 m phosphate buffer 
(pH = 7.4) in order to avoid the influence of pH on PGA sec-
ondary structure. Therefore, we attributed the observed changes 
in conformation exclusively to the modifications performed.[39] 
PGA-(AGM)LL-Dox demonstrated a trend toward an alpha-helix 
conformation. The native secondary structure expected for 
PGA backbone seems to govern the overall conformation with 
increasing hydrophilic Gly linker length. Interestingly, the per-
centage of modification also influenced the disruptive effect of 
the linker; comparisons between PGA-(G-AGM)LL-Dox and PGA-
(G-AGM)HL-Dox demonstrated that the significant trend to par-
tial alpha-helix structure can only be attributable to the increase 
of G-AGM moiety loading. G-AGM appears to partially shift the 
secondary structure to alpha-helix again, even more markedly 
than in the parent conjugate with direct attachment of drugs.
In order to ascertain how these observations at molecular 
level correlate with the polymer–drug conjugate conformations 
adopted in solution, we studied selected samples by SANS. 
The scattering data obtained for PGA-(AGM)LL-Dox, PGA-(G-
AGM)LL-Dox, PGA-(G-AGM)HL-Dox, and PGA-(GG-AGM)LL-
Dox are shown on a log–log plot in Figure 5E. We fitted the 
data according to a broad peak model[40] (see Figure S15, Sup-
porting Information, for fitting details and complete analysis). 
The predominant conformation of PGA in its protonated state 
Adv. Funct. Mater. 2018, 1800931
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Figure 4. Antitumor activity and safety of PGA-(G-AGM)LL-Dox and PGA-(G-AGM)HL-Dox in an orthotopic 4T1 breast tumor mice model. A) The 
combination conjugates PGA-(G-AGM)HL-Dox inhibited tumor volume growth more than PGA-(G-AGM)LL-Dox, the simple conjugate or the combination 
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in solution at low concentration is a helical structure at the 
molecular scale, giving rise to rod-like molecules at acidic pH, 
while random coil is the preferred conformation in the carboxy-
late form (pH > pKa).[39] These helixes associate in solution to 
form larger clusters that have an internal structure arising from 
alignment of the individual rod-like PGA molecules. Apart 
from the conjugate PGA-(G-AGM)HL-Dox (68 nm), the total size 
of the clusters is outside of the accessible Q range for SANS, 
in agreement with the volume and/or intensity data obtained 
by DLS where the large-sized aggregates population has a 
much pronounced contribution to the overall size distribution 
(Figure S16, Supporting Information). However, detailed infor-
mation can be provided on the alignment and spacing of mole-
cules within the clusters. Due to the low drug loading and the 
single contrast (H-conjugate in D2O), the PGA polymer back-
bone dominated the observed scattering. Hence, the SANS data 
provide information on how the drug and linker conjugation 
affect the PGA solution structure. The higher slope of the low 
Q scattering data (n) for the PGA-(GG-AGM)LL-Dox, PGA-(G-
AGM)LL-Dox, and PGA-(G-AGM)HL-Dox conjugates compared 
to PGA-(AGM)LL-Dox suggests a fundamental difference in 
structure of the aggregates formed by these conjugates. Fit-
ting parameters for PGA-(GG-AGM)LL-Dox, PGA-(G-AGM)LL-
Dox, and PGA-(G-AGM)HL-Dox are indicative of more collapsed 
clusters (i.e., in the globular state with less free space within 
the scattering body, see Figure S15, Supporting Information, 
for full discussion). For the PGA-(AGM)LL-Dox conjugate, fit-
ting data suggested a more open Gaussian-like structure at this 
length scale (i.e., that the clusters are likely to be less densely 
internally packed). This would be in agreement with the 
measured size distributions by number shown in Figure 5B, 
where the large aggregates are outweighed, and hence the pre-
dominant clusters sizing follow the trend PGA-(GG-AGM)LL-
Dox < PGA-(G-AGM)HL-Dox < PGA-(G-AGM)LL-Dox < PGA-
(AGM)LL-Dox with the latter showing Rh size distributions of 
100 nm in both number or intensity plots, in agreement with 
cryo-transmission electron microscopy (TEM) (Figure 5C). The 
Gly linker introduces a hydrophilic character in the AGM con-
struct, and computed LogP values (a measure of hydrophobicity 
or hydrophilicity) for AGM (1.46), G-AGM (0.09), and GG-AGM 
(−1.06) demonstrated a significant reduction of hydrophobicity 
of AGM upon Gly incorporation. Hence, PGA-(AGM)LL-Dox 
had the highest hydrophobic character, displayed the highest 
propensity to aggregate (Figure S17, Supporting Information), 
and also had the largest cluster size.
In the high Q region of the SANS data, the experiment 
probes the arrangement of chains within the cluster. Conju-
gates with low loading of AGM attached by a Gly–Gly and Gly 
linker both gave a small, broad peak (centered at Q0 = 0.062 
and 0.043 Å−1, respectively) in the scattering data (Inset in 
Figure 5E). This peak corresponds to a length scale of around 
100–140 Å (2π/Q0) within the structure, which is attributed 
to regular spacing of adjacent rigid molecules within the 
cluster. The absence of a peak for PGA-(AGM)LL-Dox and PGA- 
(G-AGM)HL-Dox indicated a loss of short range order within the 
aggregate, presumably as the effect of chain–chain charge inter-
actions is outweighed by the excluded volume requirements, 
and drug solvent effect of the attached drugs. The smaller 
Q0 value for PGA-(G-AGM)LL-Dox agrees with the lower flexi-
bility of the linking group (compared to PGA-(GG-AGM)LL-Dox) 
causing a greater perturbation of the PGA conformation. The 
peak observed in PGA-(G-AGM)LL-Dox is lost when increasing 
the AGM loading to form PGA-(G-AGM)HL-Dox. This further 
highlights drug-caused perturbation of PGA clusters.
Taken together, these data indicate that direct conjugation of 
the AGM molecules (in addition to the Dox present in all con-
jugates) disrupts the ability of the PGA to adopt its preferred 
solution conformation.[27] The flexibility introduced by the 
Gly–Gly linker allows the character of the polymer backbone to 
dominate the structures formed, with the conjugate containing 
Gly–Gly linker (most flexible) showing the scattering most 
similar to that of pure PGA (peak is present).[27] With the Gly 
linker, at low G-AGM loading the Gly affords sufficient flex-
ibility for the PGA to retain its internal ordering (peak) and the 
overall aggregated morphology (n−3). These data are consistent 
with CD spectroscopy that reports a range of helical content of 
the conjugates as discussed above (Figure 5A). Comparing the 
SANS data for these two conjugates, we start to see the influ-
ence of the additional G-AGM on the secondary structure. 
At low G-AGM loading the overall structure remains broadly 
similar to that expected for pure PGA, as described above. At 
high loading PGA-(G-AGM)HL-Dox, packing of the individual 
molecules in the clusters is less ordered, (loss of peak). This is 
presumably due to a reduction in PGA–PGA charge repulsions, 
which keep the molecules separated by the characteristic dis-
tance indicated by the peak at high Q. This lessened repulsion 
allows for closer association of the conjugate molecules, and 
the clusters become smaller and more globular (turnover at low 
Q). This smaller globular structure is a favorable result, as it is 
apparent that conjugates with such morphologies, as shown by 
SANS, give lowest IC50 values (Figures S1 and S2, Supporting 
Information).
For the PGA-(AGM)LL-Dox, PGA-(G-AGM)LL-Dox, and PGA-
(G-AGM)HL-Dox, the CD, DLS, and SANS data can help to 
correlate structure, conformation, and drug release studies 
with the biological output (Table 2). Results from in vitro and 
in vivo experiments suggest that the drug release profile is 
the main factor in the antitumor activity of this family of con-
jugates. However, for PGA-(AGM)LL-Dox exists evidence of a 
higher helical conformation and propensity to aggregate with 
the biggest cluster sizes (Figure 5B and Figure S17, Supporting 
Information) and degradation of the PGA-(±G)-drug links is not 
Adv. Funct. Mater. 2018, 1800931
of the simple conjugates (PGA-(G-AGM)HL + PGA-Dox). Data represent mean ± SEM. Statistical significance was determined using an analysis of 
variance (ANOVA) t-test, (***p < 0.005, **p < 0.01). B) Kaplan–Meier survival curves by treatment demonstrating improved overall survival for PGA-
(G-AGM)HL-Dox and PGA-(G-AGM)LL-Dox. The long-rank test demonstrated significant differences (p < 0.0001). C) Animal body weight did not sig-
nificantly decrease along the experiment. Biodistribution study of PGA-(G-AGM)HL-Dox and Dox was studied in an orthotopic 4T1 breast tumor mice 
following i.v. injection D) in a tumor and E) in blood until 24 h, and in heart, spleen, kidney, and liver at 24 h. F) The conjugate remained longer than 
Dox in the bloodstream allowing sustained state for better tumor accumulation. G) Pharmacokinetic parameters obtained from blood sample of mice 
i.v. administered with PGA-(G-AGM)HL-Dox analyzed by a bicompartment model (n = 5).
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(or certainly is less) inhibited. However, although this conju-
gate also displays by far the most efficient cellular uptake along 
the family, the simultaneous drug release and subsequent drug 
antagonism translates into low cytotoxicity. Combined with the 
identical polymer–drug linkages this accounts for the similar 
release profiles for both drugs. For the PGA-(G-AGM)LL-Dox, 
AGM was released preferentially to Dox. The more strongly hel-
ical structure of the individual PGA-(G-AGM)LL-Dox conjugate 
Adv. Funct. Mater. 2018, 1800931
Figure 5. Physicochemical characterization of selected combination conjugates PGA-(AGM)LL-Dox, PGA-(G-AGM)LL-Dox, and PGA-(G-AGM)HL-Dox. 
A) Circular dichroism data on selected conjugates in phosphate buffer 10 × 10−3 m, pH = 7.4 at 0.6 mg mL−1. B) Size distribution graphs in number 
obtained by DLS in PBS at 2 mg mL−1. C) Representative Cryo-TEM image of PGA-(AGM)LL-Dox in H2O at 2 mg mL−1, scale bar is 100 nm. D) Cellular 
uptake study of the selected conjugates by flow cytometry. Results are represented as the average of cell associated fluorescence (CAF) ± SEM. (n = 3). 
E) SANS profiles and fitting.
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molecules indicated by CD supports the lower accessibility of 
Dox and ordered spacing structures within the clusters suggests 
structure with greater accessibility for the cathepsin B cleaving 
group. It is more difficult to reconcile the release data for the 
PGA-(G-AGM)HL-Dox conjugate: lower release of AGM and 
high release of Dox. CD reports a helical structure at the molec-
ular level, SANS reports disordered clusters of molecules that 
are smaller and more densely packed than PGA-(G-AGM)LL-
Dox. Neither technique probes the detailed packing of the AGM 
around the PGA helix, but SANS assessments indicate that, at 
high G-AGM content, intermolecular interactions are AGM, 
rather than PGA, dominated. Intramolecular or indeed inter-
molecular AGM–AGM interactions may somehow be screening 
the linkers. This might also be indicative of nonrandom distri-
bution of the drug along the PGA chain at the higher loading 
either at outset, or induced as the drug loading changes at very 
low release levels. More detailed structural studies at key time-
points would be required to resolve these possibilities.
3. Conclusions
We have designed a wide family of single and combina-
tion polymer–drug conjugates aiming for efficient antitumor 
treatment for breast cancer. Within the present family of 
PGA–AGM–Dox conjugates, we ratify the importance of the 
presence of both drugs in the same polymeric carrier that 
secures their codelivery to the same cell. Of note, we paid spe-
cial attention to the interplay between biological behavior and 
determinant physicochemical properties. As expected drug 
ratio is a key feature ruling conjugate activity as seen for PGA-
(G-AGM)HL-Dox vs PGA-(G-AGM)LL-Dox in this case. More 
importantly, we discovered that the presence of the small and 
flexible Gly linker (the smallest amino acid, involving less 
than 1% of the total molecular weight of the conjugate) plays a 
decisive role in the structure of the whole macromolecule and 
hence significantly influences biological activity. The introduc-
tion of Gly induces a significant shift in drug release kinetics, 
size, secondary structure, and internal arrangement of the 
polypeptidic backbone as derived from the intensive CD, DLS, 
and SANS studies. The different configuration for Gly linker 
introduction (G or GG) between the polymer and AGM seems 
to modify the spatial disposition of the conjugate in such a way 
as to modify the disposition of the conjugate for the protease 
cleavage allowing a differential release of AGM vs Dox and 
consequently determining the final therapeutic output. It is 
clear that the kinetics of drug release is one of the major phys-
icochemical descriptors to take into account when designing 
combination therapeutics.
As seen within this work, the choice of linkers employed 
in the conjugation of active agents in a combination-polymer-
drug conjugate can endow the complex macromolecular system 
with enhanced properties. In our family of conjugates the best 
performance was seen with PGA-(G-AGM)HL-Dox, conjugate 
bearing a 2:1 (AGM: Dox) molar ratio and Gly as AGM linker. 
This combination conjugate showed significantly greater anti-
tumor effects than PGA-(G-AGM)LL-Dox (1:1 AGM: Dox molar 
ratio) and even more remark performance if compared with 
those with a direct AGM conjugation.
Our results lay the groundwork to move toward the effi-
cient design of newer conjugates with more adequate linkers 
allowing enhanced spatiotemporal control on release profiles, 
seeking for synergistic effects and, therefore, improved anti-
tumor effects. Our results also highlight the importance of an 
exhaustive supramolecular characterization to adequately com-
pare in vitro and in vivo assessments.
4. Experimental Section
Cell Culture Conditions (MCF-7-ca and 4T1): Human estrogen-
dependent breast cancer cell line MCF-7-ca (human aromatase-
transfected) was ceded from the Tenovus Centre for Cancer Research 
at Cardiff University and the 4T1 breast cancer cell line 4T1 was 
obtained from American Type Culture Collection (ATTC) (EU). MCF-
7-ca cells were maintained in Dulbecco’s modified Eagle medium 
(DMEM) supplemented with 10% heat inactivated steroid-deprived 
fetal bovine serum (SFBS) (Thermo-Fisher Scientific, USA), 10−9 m of 
oestradiol (Sigma-Aldrich, Spain, UE) and 0.75 mg mL−1 of geneticin 
G418 (Thermo-Fisher Scientific, USA) over standard cell culture 
conditions (37 °C and 5% CO2). SFBS was prepared as was previously 
described. 4T1 cells were maintained in Roswell Park Memorial 
Institute (RPMI) supplemented with 10% heat inactivated fetal bovine 
serum over standard tissue culture conditions.
Cell Viability Assays: Cell lines were seeded in sterile 96-wells 
microtiter plates at the concentration of 12 500 cells cm−2 for MCF-7-Ca 
and 6250 cells cm−2 for 4T1. Plates were incubated for 24 h and then free 
drugs and the conjugates were tested at the final concentrations ranging 
from 0 to 0.1 mg mL−1 of drug equivalents. After 72 h of treatment cell 
viability was measured using the Cell Titer 96 Aqueous nonradioactive 
cell proliferation assay (Promega, Corporation, Spain, UE) in accordance 
with the manufacturer’s instructions. The optical density of each well 
was measured at 490 nm using a Wallac 1420 Workstation (PerkinElmer, 
MA, USA). Cell viability was expressed as a percentage of the viability of 
untreated control cells.
Cellular Uptake Studies: Uptake assay was performed in MFC7-Ca cell 
line at two different temperatures, 37 and 4 °C. Cells were seeded in sterile 
six-wells plates at concentration of 32 000 cells cm−2 and incubated for 
24 h. A cathepsin B inhibitor, Leupeptin (PanReac AppliChem, VWR, UE), 
was added to each well at 100 × 10−6 m 30 min before the incubation of 
the polymer conjugates (PGA-(AGM)LL-Dox, PGA-(G-AGM)LL-Dox, PGA-
(GG-AGM)LL-Dox, and PGA-(G-AGM)HL-Dox in order to avoid polymer 
degradation. To perform the 4 °C uptake experiment, cells were preincubated 
at 4 °C during 30 min before addition of the treatments. 12 µg mL−1 of 
each polymer were tested at different time points (0–180 min). After that, 
medium was removed and two washes with PBS 0.1 wt% BSA (bovine 
serum albumin, Sigma-Aldrich, Spain, UE) were performed and finally 
cells were scraped and collected in 500 µL of PBS 0.1 wt% BSA. In order 
to detect the fluorescence into the cells, a FC500 MCL Flow Cytometer 
(Beckman-Coulter, CA, USA) was used. The cell associated fluorescence 
(CAF) was calculated based on the following formula (CAF = percentage 
positive cells x fluorescence level). The real uptake by endocytosis is the 
difference between the uptake at 37 and at 4 °C.
Orthotopic 4T1 Murine Breast Cancer Model: All the animal experiments 
were carried out in accordance with the guidelines established by the 
European communities council directive (86/609/European communities 
council (ECC)) and by Spanish Royal Decree 1201/2005 and were 
approved by the institutional Animal Care and Use Committee. Food and 
water were provided ad libitum during whole experiments in all cases and 
general aspect, behavior, and body weight were evaluated daily to ensure 
animal wellness. Six to eight weeks female Balb/c mice used for all the 
experimental procedures were purchased from Harlan Laboratories Inc. 
(Spain, EU). Tumor induction was performed by injecting 5 × 105 4T1 
cells suspended in 100 µL of Matrigel in the second left mammary fat 
pad under inhalatory anesthesia (2.5% sevoflurane in 100% oxygen).
Adv. Funct. Mater. 2018, 1800931
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Antitumor Activity of Polymer Drug Conjugates: After 8 d of cell 
inoculation, when tumor size reached 0.1 cm3, mice were split in 
representative groups and the conjugates were injected i.v. in three 
single doses of 10 mg Kg−1 Dox equivalents every three days. Free Dox 
was dissolved in saline and used as a control of free drug, administered 
at 3 mg kg−1 following the same schedule. Tumors were measured 
every 3 d with a digital caliper and volumes were obtained considering 
spheroid growth, applying the formula (height/2 x length/2 x width/2)3 x 
(4/3 Pi). Once tumors reached 1.0 cm3 (16 d after first treatment), mice 
were sacrificed under CO2 atmosphere and blood, main organs as well 
as tumors were collected for later histopathological analysis. Kaplan–
Meier survival curves were performed using GraphPad.
Biodistribution of PGA-(G-AGM)HL-Dox Combination Conjugate: Mice 
bearing 0.1 cm3 of tumor (developed as previously detailed) were used 
for biodistribution study. Single dose of 10 mg Kg−1 of Dox equivalents of 
the conjugate was i.v. administered and groups of animals (n = 6) were 
sacrificed at different time points (0, 8, 24, 48, and 72 h). Blood was 
collected and main organs and tumor were carefully and systematically 
excised, frozen, and storage at −80 °C until further analysis.
Organs and tumor were suspended in 2 mL of cold PBS and 
vigorously mixed by the use of an Ultraturrax mixer. pH of resultant 
homogeneous mix was adjusted to 8.5 by adding some drops of 1 m 
ammonium formate buffer and then extracted three times with 5.0 mL 
of a mixture of CH3Cl/iPrOH 4:1 v/v. Aqueous phases were discarded 
and supernatants were concentrated till dryness under N2 stream. Final 
residues were dissolved in 100 µL of HPLC-grade MeOH and samples 
were analyzed by  Reverse Phase-HPLC (RP-HPLC) following the same 
method for Free Drug determination already described. Final fluorescent 
measurements related to Dox were standardized according tissue weight.
Half-Life of Conjugate in Plasma: Blood from biodistribution 
experiment was centrifuged (4000 rpm, 10 min, r.t.) and plasma was 
collected. 100 µL of plasma was made up to 1.0 mL with milliQ water 
and pH was fixed to 8.5 as previously explained. Liquid–liquid extraction 
was carried out three times with 5.0 mL of a mixture of CH3Cl/iPrOH 
4:1 v/v. Organic phases were dried under N2 stream and suspended 
as already explained and analyzed by RP-HPLC under the same 
experimental conditions than for Free Drug determination.
Pharmacokinetics Analysis: The pharmacokinetics analysis was 
performed by nonlinear regression using the SOLVER function of 
Microsoft Excel[41] software as described before.[42] The pharmacokinetic 
parameters analyzed were A, B, ALPHA, BETA, Cl (D/area under the 
curve (AUC)), Vss apparent terminal half-life, and AUC.
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